Immix Biopharma (IMMX) Common Equity (2020 - 2026)
Immix Biopharma (IMMX) posted Common Equity of $84.4 million for Q1 2026, down 10.06% sequentially from $93.8 million in Q4 2025, and up 779.38% YoY from $9.6 million in Q1 2025.
Immix Biopharma (IMMX) Common Equity (2020 - 2026) Analysis & Trends
Immix Biopharma has reported Common Equity for 7 years, with the latest figure at $84.4 million in Q1 2026.
- Quarterly Common Equity rose 779.38% year-over-year to $84.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $84.4 million (up 779.38% YoY) and the FY2025 annual result came in at $93.8 million, up 607.83% from the prior year.
- Common Equity retreated to $84.4 million in Q1 2026 per IMMX's latest filing, from $93.8 million in the prior quarter.
- Over five years, Common Equity peaked at $93.8 million in Q4 2025 and troughed at $4.7 million in Q2 2025.
- A 5-year average of $24.2 million and a median of $16.7 million in 2022 frame the typical range for Common Equity.
- The sharpest annual moves came in 2025 and 2026: Common Equity plunged 80.52% in 2025, then soared 779.38% in 2026.
- Over 5 years, Common Equity stood at $13.2 million in 2022, then grew by 23.13% to $16.2 million in 2023, then slipped by 18.22% to $13.3 million in 2024, then jumped by 607.83% to $93.8 million in 2025, then declined by 10.06% to $84.4 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $84.4 million, $93.8 million, and $8.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Immix Biopharma | 784.75 Mn | 784.75 Mn | - | 228.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 228.92 Mn |
| Mar 31, 2026 | 84.36 Mn |
| Dec 31, 2025 | 93.80 Mn |
| Sep 30, 2025 | 8.26 Mn |
| Jun 30, 2025 | 4.65 Mn |
| Mar 31, 2025 | 9.59 Mn |
| Dec 31, 2024 | 13.25 Mn |
| Sep 30, 2024 | 17.55 Mn |
| Jun 30, 2024 | 23.89 Mn |
| Mar 31, 2024 | 27.63 Mn |
| Dec 31, 2023 | 16.20 Mn |
| Sep 30, 2023 | 19.65 Mn |
| Jun 30, 2023 | 13.17 Mn |
| Mar 31, 2023 | 11.74 Mn |
| Dec 31, 2022 | 13.16 Mn |
| Sep 30, 2022 | 16.75 Mn |
| Jun 30, 2022 | 18.11 Mn |
| Mar 31, 2022 | 19.65 Mn |
| Dec 31, 2021 | 17.99 Mn |
| Sep 30, 2021 | -6.20 Mn |